immunoglobulin heavy joining 1P (pseudogene)Genealiases: J-psi-1 · Jpsi1
Q-omics provides the consensus-scored IGHJ1P profile across patient tissues and cancer cell-line models. IGHJ1P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IGHJ1P is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, IGHJ1P RNA expression shows 7,147 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight UCEC, COAD, and BLCA as cancer lineages where IGHJ1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHJ1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHJ1P survival associations across molecular data types. IGHJ1P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHJ1P RNA expression–survival associations across cancer types. High IGHJ1P expression shows unfavorable associations in UCEC, CHOL, LAML, KIRP and GBM, but favorable associations in HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for IGHJ1P RNA expression.
This table summarizes IGHJ1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHJ1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHJ1P shows lower tumor expression in COAD and higher tumor expression in LUAD, BRCA and KIRC. The COAD box plot shows higher IGHJ1P RNA expression in normal versus tumor tissue (log2 FC = −0.603, t-test p < 0.001).
This table shows molecular features associated with IGHJ1P in patient tissues and cancer cell lines. In patient samples, IGHJ1P shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
